社会脆弱性指数与可切除非小细胞肺癌治疗时间之间的关联
Arsalan A Khan1, Savan K Shah1, Wara Naeem1
1Department of Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, Illinois, USA.
The Annals of thoracic surgery
|May 8, 2025
概括
社会脆弱性指数 (SVI) 和缺乏保险与非小细胞肺癌 (NSCLC) 治疗时间的延长有关. 识别社会脆弱的患者可以帮助减少癌症治疗的延迟.
科学领域:
- 在瘤学瘤学.
- 公共卫生 公共卫生
- 医疗保健服务研究 医疗服务研究
背景情况:
- 健康影响的社会决定因素非小细胞肺癌 (NSCLC) 治疗时间表.
- 在以前的研究中,量化这些社会因素一直是一个挑战.
- 社会脆弱性指数 (SVI) 为评估这些决定因素提供了定量衡量标准.
研究的目的:
- 调查社会脆弱性指数 (SVI) 与非小细胞肺癌 (NSCLC) 治疗时间之间的联系.
- 确定SVI是否可以预测NSCLC患者治疗开始的延迟.
主要方法:
- 对890名手术切除的NSCLC患者进行了回顾性队列研究 (2010-2021).
- 治疗的时间定义为从CT扫描到手术的间隔.
- 使用CDC的人口普查地带级工具计算SVI;用于评估关联的多变量线性回归.
主要成果:
- 较高的SVI独立地与治疗时间的延长有关 (β = 1.18; P < .001).
- 双重的医疗补助和医疗保险覆盖 (β = 43.85;P < .001) 和缺乏保险 (β = 79.21;P = .003) 也预测了治疗延迟.
- 治疗的中位时间为35天,较高的SVI与较长的间隔相关.
结论:
- 较高的SVI,医疗补助/医疗保险覆盖率和无保险身份与较长的NSCLC治疗持续时间有关.
- SVI可以作为一种有价值的工具来识别患有延迟癌症治疗风险的患者.
- 这凸显了在NSCLC护理途径中解决社会决定因素的干预措施的需要.
相关概念视频
01:21Cancer Survival Analysis
301
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
301
01:20Comparing the Survival Analysis of Two or More Groups
88
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
88
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:18Introduction To Survival Analysis
122
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
122
01:20Actuarial Approach
41
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
41
02:49Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K